Clinical Trial

Study of BHV-1400 in IgA Nephropathy

Name: Study of BHV-1400 in IgA Nephropathy — clinical trial record (NCT07054684)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).

Protocol Amendment History 1 change

notable Trial sites expanded: 12 -> 15 locations 2026-06-03

Trial Details

NCT Number	NCT07054684
Lead Sponsor	Biohaven Therapeutics Ltd.
Conditions	IgA Nephropathy
Enrollment	20 participants
Start Date	2025-07-30
Primary Completion	2027-07 (estimated)
Study Completion	2027-07 (estimated)
Updated on ClinicalTrials.gov	2026-06-23